← All trials
NCT06389513
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 12, 2024
- Primary completion
- Apr 30, 2025
- Completion date
- Apr 30, 2025
- First posted
- Apr 29, 2024
- Last posted
- Jun 24, 2024
- Enrollment
- 3000
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tianjin Cansino Biotechnology IncLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.